Disease Areas

Inflammation is part of the body’s complex biological response to harmful stimuli, such as pathogens, damaged cells or irritants.

While inflammation is part of the body’s natural protection mechanism, miscues in the inflammatory pathways are also associated with a broad range of diseases, such as arthritis, asthma, psoriasis and many autoimmune conditions. As a result, the unmet need for new anti-inflammatory therapeutics is substantial.

We recently entered the field of inflammatory diseases as a natural evolution of our focus on cancer, given the number of molecular targets and cellular pathways that have broad applicability across inflammatory disease and oncology. For example, we are developing IPI-145, a potent oral, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. IPI-145 has demonstrated activity in several preclinical models of inflammation, and we are now conducting a Phase 1 trial in healthy adult subjects. The data from this trial will inform our Phase 2 development plan in inflammation.

With our strong scientific capabilities and proven ability to conduct early development of product candidates outside of oncology, we believe we have the expertise to reveal – and then realize – the potential of our drug candidates in the diverse and complex field of inflammatory conditions.